Physician profile
Ingrid M Brown
NPI 1952309726
$2,324.71
in general payments reported to CMS, 2019-2025
32 companies · $840 in 2025
The $840 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.79 · 2020: $50.91 · 2021: $332 · 2022: $254 · 2023: $252 · 2024: $538 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.99 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $383.39 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $260.01 | 2022-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $208.62 | 2023-2025 | Viberzi, Linzess |
| Lilly USA, LLC | $148.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $133.35 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $120.47 | 2020-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $100.29 | 2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $93.78 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $93.56 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.69 | 2021-2024 | Synjardy, Jardiance |
| Aimmune Therapeutics, INC. | $72.82 | 2025 | Zenpep |
| Xeris Pharmaceuticals, INC. | $71.58 | 2022-2024 | Gvoke Hypopen |
| Pfizer INC. | $65.63 | 2022-2023 | |
| Dexcom, INC. | $60.56 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $58.29 | 2023-2025 | Korlym |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $49.13 | 2021-2022 | |
| Cequr Corporation | $38.86 | 2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $34.82 | 2021-2024 | Vaxneuvance, Gardasil, Capvaxive |
| Shire North American Group INC | $33.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.74 | 2021-2024 | Eohilia |
| Kowa Pharmaceuticals America, INC. | $25.43 | 2019-2021 | |
| Amarin Pharma, INC. | $21.45 | 2021 | |
| Clarus Therapeutics INC. | $20.23 | 2021 | |
| Zealand Pharma US, INC. | $18.76 | 2021 | |
| Daiichi Sankyo INC. | $18.32 | 2023 | Injectafer |
| Tandem Diabetes Care, INC. | $17.10 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ucb, INC. | $16.49 | 2022 | |
| Insulet Corporation | $15.68 | 2021 | |
| Esperion Therapeutics, INC. | $13.86 | 2021 | |
| Glaxosmithkline, LLC. | $12.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.44 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.